** Nyrada NYR.AX soars 9.2% to A$0.083, highest since Jan. 23; set for biggest intraday pct gain since Dec. 16, 2024
** Biotechnology co gets Human Research Ethics Committee's (HREC) approval to start its first-in-human Phase Ia clinical trial for its lead drug candidate NYR-BI03
** NYR-BI03 is used to treat stroke, traumatic brain injury
** Stock down 8.5% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.